Opendata, web and dolomites

iHEAR SIGNED

Gene therapy of inherited and acquired hearing loss

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iHEAR project word cloud

Explore the words cloud of the iHEAR project. It provides you a very rough idea of what is the project "iHEAR" about.

clinically    ipsc    600    receptor    proteins    360    hearing    human    aav    transduction    marker    world    treat    monogenetic    correct    patients    strategies    lines    whom    samples    stem    generate    experiments    genome    social    corrective    vector    models    demonstrated    genes    congenital    transfer    wp1    wp3    patient    vitro    safety    vivo    spiral    neurons    transgene    treatment    wp2    gene    hair    once    designs    inner    collection    fluorescent    hc    toolbox    proper    alterations    protective    burden    primary    model    incl    mouse    therapeutic    employed    inducible    financial    inherited    sgn    impaired    lentiviral    people    precision    promoters    viral    cells    therapy    medicine    proof    acquired    constructs    causative    appropriate    performing    pluripotent    opportunity    expression    vectors    configurations    translatable    explored    substantial    ear    mirnas    optimized    children    ganglion    otic    efficient    caused    tools    adeno    protect    cell    mutations    translatability    efficiency    million    editing    murine    perform   

Project "iHEAR" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙999˙500 €
 EC max contribution 1˙999˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙999˙500.00

Map

 Project objective

To address the substantial financial and social burden caused by hearing loss in 360 million people world-wide, I aim to improve hearing via gene therapy to correct inherited and protect from acquired hearing loss. In vitro experiments will establish the best vector configurations for transfer of therapeutic genes and miRNAs into inner ear hair cells (HC) and spiral ganglion neurons (SGN). The efficiency of the best-performing vector designs will then be explored in vivo using fluorescent marker proteins. Cell-type specific and inducible promoters as well as receptor-targeted vectors will be employed as a safety measure and to ensure transgene expression in HC and SGN target cells. Once efficient transduction of appropriate target cells and proper expression of therapeutic proteins are demonstrated, I will perform proof-of-concept studies in hearing loss models, incl. established mouse models, to correct (WP1) or protect (WP2) from impaired hearing. To ensure translatability of these findings, I will generate human induced pluripotent stem cells (iPSC) from patients with hearing loss (WP3), so that I can test optimized constructs in human otic cells. Moreover, I have access to a collection of well-characterized samples from over 600 hearing loss patients, including children with congenital hearing loss in whom many novel monogenetic alterations were identified. These resources provide the unique opportunity to generate a novel toolbox for the treatment of hearing loss. In addition to lentiviral and adeno-associated viral (AAV) vector delivery of corrective or protective genes to treat hearing loss, I will apply state-of-the-art genome editing tools to model and correct mutations causative for hearing loss in cell lines, primary cells from murine models, human patients and patient-derived iPSC. This work will contribute to development of clinically translatable approaches for precision medicine strategies to improve hearing loss treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IHEAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IHEAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

TRUST (2018)

Truth and Semantics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More